COST-EFFECTIVENESS OF PHARMACOLOGIC TREATMENT OF OVERACTIVE BLADDER

被引：0
|
作者：
Malone, D. C. [1 ]
Armstrong, E. P. [1 ]
Bui, C. [2 ]
机构：
[1] Univ Arizona, Tucson, AZ USA
[2] Astellas Pharma US Inc, Deerfield, IL USA
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 04期
关键词：
D O I：
10.1016/j.jval.2012.03.838
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A155 / A155
页数：1
相关论文
共 50 条
  • [41] COST EFFECTIVENESS OF OVERACTIVE BLADDER TREATMENT WITH MIRABEGRON IN PATIENTS IN SOUTH KOREA
    Suh, D.
    Lee, S.
    Lim, S. J.
    Song, J.
    Ko, G.
    VALUE IN HEALTH, 2016, 19 (07) : A847 - A847
  • [42] The cost effectiveness of mirabegron for the treatment of overactive bladder: three US perspectives
    Wielage, R. C.
    Perk, S.
    Campbell, N. L.
    Ng, D.
    Klein, T. M.
    Posta, L. M.
    Yuran, T.
    Klein, R. W.
    Perkins, A.
    Berner, T.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2015, 63 : S67 - S67
  • [43] Cost effectiveness and quality of life considerations in the treatment of patients with overactive bladder
    McGhan, WF
    AMERICAN JOURNAL OF MANAGED CARE, 2001, 7 (02): : S62 - S75
  • [44] Cost-Effectiveness Analysis Between Sacral Neuromodulation and OnabotulinumtoxinA for the Treatment of Refractory Overactive Bladder in Women: A Systematic Review
    Gerjevic, Kristen A.
    Ahmad, Sophia
    Strohbehn, Kris
    Riblet, Natalie
    FEMALE PELVIC MEDICINE AND RECONSTRUCTIVE SURGERY, 2021, 27 (08): : 481 - 487
  • [45] Cost-Effectiveness Analysis Between Sacral Neuromodulation and OnabotulinumtoxinA for the Treatment of Refractory Overactive Bladder in Women: A Systematic Review
    Gerjevic, Kristen A.
    Ahmad, Sophia
    Strohbehn, Kris
    Riblet, Natalie
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2021, 76 (11) : 667 - 668
  • [46] Cost-Effectiveness Analysis of Sacral Neuromodulation and Botulinum Toxin A Treatment for Patients With Idiopathic Overactive Bladder Editorial Comment
    Penson, David F.
    JOURNAL OF UROLOGY, 2011, 186 (01): : 212 - 213
  • [47] COST-EFFECTIVENESS ANALYSIS OF MIRABEGRON VERSUS TOLTERODINE EXTENDED RELEASE IN THE TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER IN THE UNITED STATES
    Xie, J.
    Zhou, Z. Y.
    Bui, C. N.
    Yan, Y.
    De, G.
    Runken, M. C.
    Wu, E. Q.
    VALUE IN HEALTH, 2012, 15 (07) : A457 - A457
  • [48] The cost-effectiveness of extended release tolterodine in the management of overactive bladder in Germany and the United Kingdom
    Anderson, P
    Resch, A
    Dooley, JA
    Brüggenjürgen, B
    Zlateva, G
    VALUE IN HEALTH, 2004, 7 (06) : 797 - 798
  • [49] COST-EFFECTIVENESS STUDY OF SECOND LINE THERAPIES IN PATIENTS WITH IDIOPATHIC OVERACTIVE BLADDER IN SPAIN
    Arlandis, S.
    Castro, D.
    Errando, C.
    Fernandez, E.
    Jimenez, M.
    Gonzalez, P.
    Crespo, C.
    Stauble, F.
    Rodriguez, J. M.
    Brosa, M.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 136 - 136
  • [50] PERCUTANEOUS NERVE STIMULATION FOR OVERACTIVE BLADDER: COST-EFFECTIVENESS COMPARED TO MONO AND DUAL PHARMACOTHERAPY
    Jenks, Julie
    Solomon, Eskinder
    Pakzad, Mahreen
    Hamid, Rizwan
    Greenwell, Tamsin
    Ockrim, Jeremy
    JOURNAL OF UROLOGY, 2016, 195 (04): : E850 - E850
12345